|
|
Home > Investor Relations > Financials
> P & L Account
> Ranbaxy Laboratories Limited |
| |
P & L
Account
Untitled Document
| PROFIT
AND LOSS ACCOUNT
FOR THE YEAR ENDED DECEMBER 31, 2006 |
| |
|
Rs. in Million |
| |
Sche
dule |
2006 |
2005 |
| INCOME |
|
|
|
| Operating income |
15 |
40,259.40 |
36,517.69 |
| Less : Excise duty |
|
481.72 |
820.00 |
| |
|
39,777.68 |
35,697.69 |
| Other income |
16 |
381.91 |
904.80 |
| |
|
40,159.59 |
36,602.49 |
| EXPENDITURE |
|
|
|
| Materials |
17 |
16,323.82 |
15,048.92 |
| Manufacturing |
18 |
1,997.09 |
1,752.91 |
| Personnel |
19 |
3,310.85 |
3,016.52 |
| Selling, general and administration |
20 |
8,582.78 |
8,741.76 |
| Research and development |
21 |
3,863.35 |
4,863.60 |
| |
|
34,077.89 |
33,423.71 |
| PROFIT FROM OPERATIONS BEFORE
INTEREST, DEPRECIATION,
AMORTIZATION AND IMPAIRMENT |
|
6,081.70 |
3,178.78 |
| Interest |
|
584.44 |
264.11 |
| Depreciation, amortization and
impairment |
22 |
1,067.50 |
1,013.33 |
| Profit from operations |
|
|
|
| Continuing operations |
|
4,429.76 |
1,731.68 |
| Discontinued operations |
|
– |
169.66 |
| Profit from operations
before exceptional items |
|
4,429.76 |
1,901.34 |
| Profit from sale of undertaking |
|
– |
112.29 |
| Profit before tax |
|
4,429.76 |
2,013.63 |
| Provision for tax |
23 |
624.33 |
(223.35) |
| Profit after tax |
|
3,805.43 |
2,236.98 |
| Tax - earlier years |
|
145.84 |
(116.56) |
| Balance as per last balance sheet |
|
560.34 |
2,270.05 |
| Transfer from Foreign projects reserve |
|
22.95 |
30.65 |
| Balance available for appropriation |
|
4,534.56 |
4,421.12 |
| APPROPRIATIONS |
|
|
|
| Dividend |
|
|
|
| Interim |
|
3,168.94 |
931.11 |
| Final |
|
– |
2,235.55 |
| Tax on dividend |
|
444.44 |
444.12 |
| Transfer to General reserve |
|
450.00 |
250.00 |
| Surplus carried forward |
|
471.18 |
560.34 |
| |
|
4,534.56 |
4,421.12 |
| EARNINGS PER SHARE (Rs.) |
24 |
|
|
| Including discontinued operations and exceptional
items |
|
|
|
| Basic |
|
10.60 |
5.70 |
| Diluted |
|
9.87 |
5.68 |
| Excluding discontinued operations and exceptional
items |
|
|
|
| Basic |
|
10.60 |
5.14 |
| Diluted |
|
9.87 |
5.12 |
| SIGNIFICANT ACCOUNTING POLICIES |
25 |
|
|
| NOTES TO THE FINANCIAL STATEMENTS |
26 |
|
|
The schedules referred to above form
an integral part of the financial statements
This is the profit and loss account referred to in our report of
even date. |
| |
On behalf of the Board of Directors |
For WALKER, CHANDIOK & CO
Chartered Accountants |
TEJENDRA KHANNA
Chairman
|
| VINOD CHANDIOK
Partner
Membership No. 10093
|
DR. BRIAN W. TEMPEST
Chief Mentor &
Executive Vice Chairman
MALVINDER MOHAN SINGH
CEO & Managing Director
|
| |
ATUL SOBTI
Chief Operating Officer &
Whole-time Director
|
| |
RAM S. RAMASUNDAR
President & CFO
|
| Place : Gurgaon
Dated : March 29, 2007
|
SUSHIL K. PATAWARI
Secretary
|
|
|
|